glp-1 price reduction As costs of weight loss drugs like Wegovy and Zepbound go down, how low can prices go? A Value-Based Price for Anti-Obesity
Description
This hypothesis was supported by the Gorelik study which found no benefit in non-obese patients 92 whilst a smaller study by Anderson et al
No class action lawsuits have been filed against Ozempic
1 Behind the scenes, though, GLP-1s are raising difficult questions about who has access to the drugs, the long-term health effects and how much the growing demand will drive up health spending
Meanwhile, a man and his wife have filed a lawsuit against Novo Nordisk, the maker of Wegovy and other semaglutide products
Insurance is not accepted, but HSA and FSA payments are eligible
The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
